Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,861 matching trials from the live ClinicalTrials.gov search.
Conditions
Suicide Risk, Major Depressive Disorder (MDD)
Interventions
Suvorexant (dual orexin receptor antagonist)
Drug
Lead sponsor
Marianne Goodman
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine succinate sustained release 50 mg, Desvenlafaxine succinate sustained release 25 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Beverly Hills, California • Encino, California • Los Alamitos, California + 16 more
Conditions
Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD)
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
Sherwood Brown, MD, PhD
Other
Eligibility
21 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Dallas, Texas • Richardson, Texas
Recruiting No phase listed Observational Accepts healthy volunteers

fNIRS for Disorders of Consciousness

NCT07485361
Conditions
Disorders of Consciousness Due to Severe Brain Injury, Disorders of Consciousness, Coma, Minimally Conscious State, Unresponsive Wakefulness Syndrome, Brain Injury, TBI Traumatic Brain Injury
Interventions
Functional Near-Infrared Spectroscopy Monitoring
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Bipolar II Disorder, Bipolar II Disorder, Most Recent Episode Major Depressive
Interventions
Device: Stimulation-ON, Device: Stimulation-OFF, Device: Stimulation -ON Active Control
Device
Lead sponsor
Andrew Krystal
Other
Eligibility
22 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
San Francisco, California
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Influenza Challenge in Mood Disorders

NCT02415166
Conditions
MAJOR DEPRESSIVE DISORDER
Interventions
INFLUENZA VACCINE, NaCl-saline placebo
Biological · Other
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tulsa, Oklahoma
Conditions
Major Depressive Disorder \(MDD, Depressive Disorder, Major
Interventions
Active VeNS Device, Sham VeNS Device
Device
Lead sponsor
Neurovalens Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Conditions
Substance Abuse, Substance Dependence, Depressive Disorder
Interventions
Group interpersonal psychotherapy (IPT-G), Psychoeducation on co-occurring disorders (PSYCHOED)
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cranston, Rhode Island
Conditions
Depression, Insomnia
Interventions
CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS, Repetitive Transcranial Magnetic Stimulation
Behavioral · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Major Depressive Disorder
Interventions
NMRA-335140, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
57
States / cities
Encino, California • Garden Grove, California • Los Alamitos, California + 42 more
Conditions
Major Depressive Disorder
Interventions
Brain stimulation
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder
Interventions
Cognitive Therapy, Supportive-Expressive Psychodynamic Therapy
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Restless Leg Syndrome (RLS), Spinal Cord Stimulation (SCS)
Interventions
Spinal Cord Stimulation
Device
Lead sponsor
Marshall Holland
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2034
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Phase 2 Interventional Results available

Targeting IL-17A for Treatment-Resistant Depression

NCT04979910
Conditions
Major Depressive Disorder
Interventions
Ixekizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
79
States / cities
Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 76 more
Conditions
Major Depressive Disorder, Recurrent, Unspecified, Major Depressive Disorder, Single Episode, Unspecified
Interventions
H-Coil Deep TMS in combination with SSRIs
Device
Lead sponsor
Brainsway
Industry
Eligibility
22 Years to 68 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Davis, California • Los Angeles, California • Santa Monica, California + 9 more
Conditions
Major Depression, Cancer, Diabetes, Cardiovascular Diseases
Interventions
Desvenlafaxine, Omega 3 Fatty acids, Placebo (for Omega 3 fatty acid supplement)
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Farmington, Connecticut
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ketamine in the Treatment of Depression

NCT01558063
Conditions
Major Depressive Disorder
Interventions
Ketamine, Saline, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder
Interventions
Aripiprazole 5mg, Aripiprazole 2mg, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chronic Kidney Diseases, Major Depressive Disorder, End Stage Kidney Disease (ESRD)
Interventions
Bupropion, Behavioral activation therapy, Placebo, Clinical Management
Drug · Behavioral · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Stony Brook, New York • Dallas, Texas • Seattle, Washington
Conditions
Major Depressive Disorder
Interventions
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Drug
Lead sponsor
Adams Clinical
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Watertown, Massachusetts
Completed Phase 2 Interventional

ALTO-300 in Depression

NCT05118750
Conditions
Major Depressive Disorder
Interventions
ALTO-300 oral (PO) tablet
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 74 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Culver City, California • Sacramento, California • Santee, California + 8 more
Completed Phase 4 Interventional Results available

Treatment of Nicotine Dependence and Acute Depression

NCT00186446
Conditions
Major Depressive Disorder, Nicotine Dependence
Interventions
bupropion and smoking cessation behavioral intervention
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Stanford, California
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
Dose-Optimized and Spaced Transcranial Direct Current Stimulation, Spaced Transcranial Direct Current Stimulation, Sham Transcranial Direct Current Stimulation
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California